Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH-Mutant Tumors Vulnerable to PARP Inhibition.

Cancer discovery - 1 Apr 2017

Abstract excerpt

Several cancers, including glioma and acute myeloid leukemia, carry mutations in IDH1 or IDH2 Researchers have found that these mutations impair homologous recombination, making the tumors sensitive to PARP inhibition. They showed that one such inhibitor, olaparib, killed IDH1/2-mutant cancer cells in culture and slowed tumor growth in mice.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Homologous Recombination
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28228392
DOI: 10.1158/2159-8290.CD-NB2017-026

Genes

IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH-Mutant Tumors Vulnerable to PARP Inhibition.PMID 28228392Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burdenSemantic proximity Read ↗

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsSemantic proximity Read ↗

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.Semantic proximity Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.Semantic proximity Read ↗

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.Semantic proximity Read ↗

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.Semantic proximity Read ↗

Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.Semantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read ↗

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read ↗

HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancerSemantic proximity Read ↗

Anticancer drugs: IDH2 drives cancer in vivo.Semantic proximity Read ↗

Heterochromatin-Dependent Replication Stress: A Lesson from IDH1/2 Mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.